CX Institutional
BIIB icon

CX Institutional’s Biogen BIIB Stock Holding History

CX Institutional’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$385K Buy
1,704
+3
+0.2% +$636 0.01% 536
2026
Q2 		$368K Sell
1,701
-24
-1% -$4.59K 0.01% 554
2026
Q1 		$316K Buy
1,725
+19
+1% +$3.5K 0.01% 589
2025
Q4 		$300K Buy
1,706
+253
+17% +$41.3K 0.01% 584
2025
Q3 		$204K Buy
1,453
+83
+6% +$11.2K 0.01% 689
2025
Q2 		$172K Buy
1,370
+55
+4% +$6.85K 0.01% 674
2025
Q1 		$180K Buy
+1,315
New +$188K 0.01% 626
2024
Q3 		– Sell
-1,005
Closed -$233K – 556
2024
Q2 		$233K Buy
+1,005
New +$218K 0.01% 507
2024
Q1 		– Sell
-865
Closed -$224K – 546
2023
Q4 		$224K Buy
+865
New +$212K 0.01% 469
2023
Q3 		– Sell
-712
Closed -$203K – 487
2023
Q2 		$203K Buy
+712
New +$212K 0.01% 500
2022
Q3 		– Sell
-93
Closed -$19K – 525
2022
Q2 		$19K Buy
+93
New +$19K ﹤0.01% 850
2021
Q4 		– Sell
-320
Closed -$91K – 392
2021
Q3 		$91K Sell
320
-15
-4% -$4.92K 0.01% 464
2021
Q2 		$116K Buy
335
+97
+41% +$29.4K 0.01% 416
2021
Q1 		$67K Buy
238
+30
+14% +$8.09K 0.01% 430
2020
Q4 		$51K Buy
208
+63
+43% +$16.3K ﹤0.01% 434
2020
Q3 		$41K Buy
145
+77
+113% +$21.5K ﹤0.01% 417
2020
Q2 		$18K Sell
68
-19
-22% -$5.71K ﹤0.01% 460
2020
Q1 		$28K Buy
87
+30
+53% +$9.1K ﹤0.01% 343
2019
Q4 		$17K Buy
57
+36
+171% +$10K ﹤0.01% 362
2019
Q3 		$5K Sell
21
-32
-60% -$7.45K ﹤0.01% 568
2019
Q2 		$12K Buy
53
+1
+2% +$231 ﹤0.01% 456
2019
Q1 		$12K Buy
+52
New +$16.4K ﹤0.01% 434

Other funds holding BIIB

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
Artemis Investment Management
Artemis Investment Management Edinburgh, United Kingdom $11.5B AUM 61.77% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return
Beau Ventures, LLc
Beau Ventures, LLc Pittsford, New York $1.06B AUM 83.06% 1-Year Est. Return
Adams Diversified Equity Fund
Adams Diversified Equity Fund Baltimore, Maryland $3.3B AUM 38.12% 1-Year Est. Return
Banque Pictet & Cie
Banque Pictet & Cie Geneva 73, Switzerland $14.5B AUM 33.71% 1-Year Est. Return
Gateway Investment Advisers
Gateway Investment Advisers Cincinnati, Ohio $11B AUM 34.31% 1-Year Est. Return
North Growth Management
North Growth Management Vancouver, British Columbia, Canada $743M AUM 74.29% 1-Year Est. Return
Fideuram - Intesa Sanpaolo Private Banking
Fideuram - Intesa Sanpaolo Private Banking Turin $3.5B AUM 45.13% 1-Year Est. Return

CX Institutional's BIIB Position: Q3 2026 in Review

CX Institutional increased its Biogen (BIIB) stake by 0.18% in Q3 2026, buying an estimated $636 and bringing the position to 1,704 shares worth $385K. The position accounts for 0.01% of the portfolio, ranked #536.

CX Institutional first reported a position in BIIB in Q1 2019 and has held it in 22 quarters since. 232 funds tracked by Wall St. Rank hold BIIB as of Q3 2026.

  • CX Institutional held 1,704 shares of Biogen worth $385K as of Q3 2026.
  • CX Institutional bought 3 Biogen shares in Q3 2026, an estimated $636.
  • Biogen made up 0.01% of CX Institutional's portfolio in Q3 2026, its #536 holding.
  • CX Institutional first reported a position in Biogen in Q1 2019 and has held it in 22 quarters since.
  • 232 funds tracked by Wall St. Rank held Biogen as of Q3 2026.

Based on CX Institutional's 13F filing for Q3 2026, filed 2 Oct 2026.